Hui-Gene Therapeutics
Latest round
- Series C
Last raised
- May 2022
Total raised
- $4.3M
Investors
- 6
About Hui-Gene Therapeutics
Based in Shanghai, China and established in 2018, Hui-Gene Therapeutics is a biotechnology company that focuses on gene research, gene editing technology, and gene therapy solutions. The company has 5500 square meter research laboratory, about 10 development pipeline and 200 staffs in R&D team. The founders Linyu Shi and Xuanyao are doctors from Developmental biology and Department of neurology of Chinese Academy respectively. The company is an innovative biopharmaceutical company focusing on gene editing technology and gene therapy drug development. It focuses on RNA gene editing technology and gene therapy preclinical research and development platform, its pipeline covers neurodegenerative diseases, visual disorders, hearing disorders and other diseases.
Who invested in Hui-Gene Therapeutics
6 investors across 3 rounds
See all investors in Hui-Gene Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hui-Gene Therapeutics
Who invested in Hui-Gene Therapeutics?
Hui-Gene Therapeutics has 6 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hui-Gene Therapeutics raised?
Hui-Gene Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Hui-Gene Therapeutics last raise money?
Hui-Gene Therapeutics's most recent round on record is a Series C, in May 2022.
What does Hui-Gene Therapeutics do?
Based in Shanghai, China and established in 2018, Hui-Gene Therapeutics is a biotechnology company that focuses on gene research, gene editing technology, and gene therapy solutions.
Where is Hui-Gene Therapeutics headquartered?
Hui-Gene Therapeutics is headquartered in Shanghai, China.
Which VCs invest in companies like Hui-Gene Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Hui-Gene Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Hui-Gene Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.